title: Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and zanamivir antiviral drugs.
abstract: Neuraminidase inhibitors (NAIs) oseltamivir and zanamivir are currently the only effective antiviral drugs available worldwide for the management of influenza. The potential development of resistance is continually threatening their use, rationalizing and highlighting the need for a close and sustained evaluation of virus susceptibility. This study aimed to analyze and characterize the phenotypic and genotypic NAIs susceptibility profiles of A(H1N1)pdm09 viruses circulating in Portugal from 2009 to 2010/2011. A total of 144 cases of A(H1N1)pdm09 virus infection from community and hospitalized patients were studied, including three suspected cases of clinical resistance to oseltamivir. Oseltamivir resistance was confirmed for two of the suspected cases. Neuraminidase (NA) H275Y resistant marker was found in viruses from both cases but for one it was only present in 26.2% of virus population, raising questions about the minimal percentage of resistant virus that should be considered relevant. Cross-decreased susceptibility to oseltamivir and zanamivir (2-4 IC50 fold-change) was detected on viruses from two potentially linked community patients from 2009. Both viruses harbored the NA I223V mutation. NA Y155H mutation was found in 18 statistical non-outlier viruses from 2009, having no impact on virus susceptibility. The mutations at NA N369K and V241I may have contributed to the significantly higher baseline IC50 value obtained to oseltamivir for 2010/2011 viruses, compared to viruses from the pandemic period. These results may contribute to a better understanding of the relationship between phenotype and genotype, which is currently challenging, and to the global assessment of A(H1N1)pdm09 virus susceptibility profile and baseline level to NAIs.
authors.affiliation: Department of Infectious Diseases, National Health Institute Doutor Ricardo Jorge, Lisbon, Portugal.
authors.forename: Vanessa
authors.initials: V
authors.lastname: Correia
authors.forename: Luis A
authors.initials: LA
authors.lastname: Santos
authors.forename: Marta
authors.initials: M
authors.lastname: Gíria
authors.forename: Maria M
authors.initials: MM
authors.lastname: Almeida-Santos
authors.forename: Helena
authors.initials: H
authors.lastname: Rebelo-de-Andrade
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000494:pharmacology*; D024882:Drug Resistance, Viral; D005260:Female; D006801:Humans; D007223:Infant; D053118:Influenza A Virus, H1N1 Subtype / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics / Q000302:isolation & purification; D007251:Influenza, Human / Q000821:virology; D020128:Inhibitory Concentration 50; D008297:Male; D008875:Middle Aged; D020125:Mutation, Missense; D009439:Neuraminidase / Q000235:genetics; D053139:Oseltamivir / Q000494:pharmacology*; D011174:Portugal; D014764:Viral Proteins / Q000235:genetics; D053243:Zanamivir / Q000494:pharmacology*
chemical_list: D000998:Antiviral Agents; D014764:Viral Proteins; D053139:Oseltamivir; C487630:NA protein, influenza A virus; D009439:Neuraminidase; D053243:Zanamivir
keywords: A(H1N1) 2009 pandemic variant; NA H275Y; NA I223V; Portugal; neuraminidase inhibitors; susceptibility testing